Amyris: Funding, Investors & Team (Sep 2026)
Amyris Biotechnologies creates renewable products that focus on fuels and chemicals that provide no-compromise sustainable alternatives to a broad range of petroleum-sourced products. It uses an industrial synthetic biology platform that applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. Its technology creates products that support biopharmaceutical drug discovery and production, from cosmetic emollients and fragrances to fuels, solvents, lubricants, and nutraceuticals.
Amyris has raised $400M across 1 funding round on record, the most recent a Post-IPO Debt of $400M announced in Nov 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Amyris Company Profile and Key Stats
Latest funding round on record: Nov 2021.
Amyris Funding Rounds
Amyris Founders and Leadership Team
No contact details are on record for this team yet.
Amyris Funding Compared to Other Biotechnology Startups
Amyris' latest round of $400M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Amyris in Biotechnology and Emeryville
Companies Similar to Amyris
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Amyris Funding FAQs
What does Amyris do?
Amyris Biotechnologies creates renewable products that focus on fuels and chemicals that provide no-compromise sustainable alternatives to a broad range of petroleum-sourced products. It uses an industrial synthetic biology platform that applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. Its technology creates products that support biopharmaceutical drug discovery and production, from cosmetic emollients and fragrances to fuels, solvents, lubricants, and nutraceuticals.
How much funding has Amyris raised?
Amyris has raised $400M across 1 round on record. The most recent is a Post-IPO Debt of $400M announced in Nov 2021.
When did Amyris last raise funding?
Amyris' most recent funding round on record is a Post-IPO Debt of $400M, announced in Nov 2021.
Who is the CEO of Amyris?
John Melo is listed as CEO at Amyris.
Where is Amyris headquartered?
Amyris is based in Emeryville, California, United States.
How many employees does Amyris have?
Amyris is in the 501-1000 employee band.
How does Amyris' funding compare to other Biotechnology startups?
Amyris' latest round of $400M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Amyris Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Amyris is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.